Login

Gabriele Solarini Paviotti, account relationship leader at Auxiell, interviews Gianmarco Lanza, President and CEO of FAE Technology. 00:10:00

Share On Facebook Share On Twitter

Videointervista Gianmarco Lanza – CEO FAE Technology

Recent Videos

00:10:00
Dryden Gold Secures $20M+ War Chest, Delivers High-Grade Discoveries and Expands Drill Targets Across Gold Rock District|Trey Wasser,CEO & Director,Dryden Gold
00:10:00
Mitchell Services Targets $50–60M EBITDA as Rig Utilization Drives Earnings Upside| Andrew Elf,CEO,Mitchell Services Limited
00:10:00
Lomiko Metals Reports Strong Pre-Feasibility Results with $800M NPV, Advancing High-Growth Graphite Projects|Gordana Slepcev,CEO,Lomiko Metals Inc.4
00:10:00
Generative AI Meets Wet Lab: Absci Accelerates Biologic Development with Hybrid Business Model|Sean McClain,CEO,Absci
00:10:00
Obliva Aims to Transform Lives of Children with Rare Mitochondrial Disorders|Ellen K. Donnelly ,CEO,Abliva AB7
00:10:00
Abionic Repositions Bio-HDL Therapy CCR001 for Rare Kidney and Eye Disorders with Promising Early Results|Cyrille Tupin,CEO,ABIONYX Pharma
00:10:00
Abingdon Health Reports 45% H1 Revenue Growth Amid Strategic Expansion and Large Contract Wins|Dr Chris Hand,Chairman,Abingdon Health
00:10:00
EB-101 Gene Therapy Shows Promising Results in Treating Recessive Dystrophic EB|Vishwas Seshadri,CEO,Abeona Therapeutics
00:10:00
Revolutionizing Trauma Care: How AAP’s Silver Technology is Fighting Deadly Implant Infections|Rubino Di Girolamo,CEO,aap Implantate AG
00:10:00
Revolutionizing Cancer Treatment: Tumor-Agnostic mTOR Targeting Shows Breakthrough Success in Rare and Genetic-Driven Tumors| Neil Desai, Founder, Executive Chairman ,Aadi Bioscience
00:10:00
Millions Affected, No Approved Cure: 89bio Advances New Therapy for NASH|Rohan Palekar,CEO,89bio Inc2
00:10:00
Malaria Prevention Drug Arakoda Positioned to Drive Future Growth for 60 Degrees Pharmaceuticals|Geoffrey Dow,President,60 Degrees Pharmaceuticals
00:10:00
4DMedical Revolutionizes Lung Imaging with CTVQ: Turning a Simple CT Scan into Functional Lung Diagnostics|Dr Andreas Fouras,CEO,4Dmedical Ltd
00:10:00
4DMedical Revolutionizes Lung Imaging with CTVQ: Turning a Simple CT Scan into Functional Lung Diagnostics|Dr Andreas Fouras,CEO,4Dmedical Ltd
00:10:00
4basebio CEO Heikki Lanckriet Unveils Vision for Next-Generation Synthetic DNA and Gene Therapy Components|Heikki Lanckriet,CEO,4basebio
00:10:00
Jim Woody on Leading 180 Life Sciences: Advancing Breakthrough Biologic Therapies for Inflammation, Fibrosis, and Pain|Dr. Jim Woody,CEO,180 Life Sciences

Suggestions

00:10:00
Interview with Ole Henson, Head of Commodity Strategy at Saxo Bank: Insights on Gold and Silver Markets in 2023
00:00:00
The Scientific Citizenship Initiative - Angela H. DePace Associate Professor of Systems Biology HMS
00:10:00
RUBICONSmartCity™ is a smart city technology suite that aids city governments in running more efficient, effective, and sustainable operations.
00:10:00
Oil Rally Insights: Short-Term Gains vs. Long-Term Bear Market
00:10:00
Caledonia Mining: Expanding Zimbabwe Gold Production
00:10:00
wealth grow Investment opportunities|MARK HENTEMANN,CEO,Quantum Capital
00:10:00
Market Concentration: Magnificent 7 vs. Dividend Stocks in 2023 | Brian Lester - CHIEF INVESTMENT OFFICER of Howe & Rusling, Inc.
00:10:00
Benton Resources Secures $3M for High-Grade Copper Project Advancement
00:10:00
Stephanie Commons Updates Morgans Network on Dalrymple Bay Infrastructure's Full Year Results | Stephanie Commons - Chief Financial Officer of Dalrymple Bay Infrastructure
00:10:00
We help our customers and clients plan and achieve their most important financial goals by delivering innovative products and services through intuitive digital experiences | Abigail Johnson,Chairman and CEO,Fidelity Advisor Sustainable Multi-Asset Fund
00:10:00
Canada's Mining Innovation: Insights from MSTA CANADA at Colombia Gold Symposium 2021 | Ryan McEachern - MANAGING DIRECTOR of Mining Suppliers Trade Association CANADA
00:00:00
Cerenis Therapeutics is specialized in research & development into HDL - Jean-Louis Dasseux, President and CEO of Cerenis Therapeutics

© 2017 - Neuhu+